Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Sperm donation

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    314 result(s) found for: Sperm donation. Displaying page 1 of 16.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2019-003269-16 Sponsor Protocol Number: GS-US-320-1196 Start Date*: 2019-08-30
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 1, Single-Dose, Cross-Over Study Evaluating the Relative Bioavailability of a Pediatric Oral Granule Formulation of Tenofovir Alafenamide in Healthy Adults
    Medical condition: Chronic Hepatitis B
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10008910 Chronic hepatitis B PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-004044-37 Sponsor Protocol Number: GS-US-342-1142 Start Date*: 2017-12-07
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 1 Relative Bioavailability and Food Effect Study of a Pediatric Oral Granule Formulation of SOF/VEL in Healthy Adult Subjects.
    Medical condition: Chronic Hepatitis C virus infection
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-000821-37 Sponsor Protocol Number: GS-US-416-2124 Start Date*: 2017-02-06
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 2, Double-Blind, Randomized Study Evaluating the Safety, Tolerability, and Efficacy of GS-4997 in Combination with Prednisolone versus Prednisolone Alone in Subjects with Severe Alcoholic H...
    Medical condition: Alcoholic Hepatitis
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004871 10001624 Alcoholic hepatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) BE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-004489-85 Sponsor Protocol Number: MORAb-009-201 Start Date*: 2015-11-03
    Sponsor Name:Morphotek Inc
    Full Title: A Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Amatuximab in Combination with Pemetrexed and Cisplatin in Subjects with Unresectable Malignant Pleural Mesothelioma
    Medical condition: Advanced pleural mesothelioma
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004864 10035605 Pleural mesothelioma malignant advanced LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-001694-32 Sponsor Protocol Number: 9785-CL-0123 Start Date*: 2017-01-17
    Sponsor Name:Astellas Pharma Global Development, Inc.
    Full Title: A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
    Medical condition: metastatic castration-resistant prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Ongoing) BE (Trial now transitioned) ES (Ongoing) GB (GB - no longer in EU/EEA) CZ (Trial now transitioned) DK (Trial now transitioned) FR (Trial now transitioned) FI (Trial now transitioned) SE (Trial now transitioned) LT (Prematurely Ended) SK (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned) NL (Ongoing) GR (Completed) AT (Trial now transitioned) NO (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-003951-39 Sponsor Protocol Number: GS-US-223-1017 Start Date*: 2019-12-09
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Di...
    Medical condition: Diabetic Kidney Disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-004418-16 Sponsor Protocol Number: B24CS Start Date*: Information not available in EudraCT
    Sponsor Name:Advicenne SA
    Full Title: A Phase 3b Open-Label Extension of Study B23CS (ARENA 2) Evaluating the Continued Safety and Efficacy of ADV7103 in Subjects With Primary Distal Renal Tubular Acidosis (ARENA 2 Open-label Extensio...
    Medical condition: Distal renal tubular acidosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10038535 Renal tubular acidosis PT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-000466-57 Sponsor Protocol Number: GS-US-216-0127 Start Date*: 2015-02-04
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 1, Single-dose Study to Evaluate the Relative Bioavailability of Cobicistat (COBI) Age-Appropriate Pediatric Tablet Formulations Compared with Adult COBI 150-mg Tablets in Healthy Adult Vo...
    Medical condition: Human Immunodeficiency Virus (HIV-1) Infections
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-002137-58 Sponsor Protocol Number: GS-US-218-1227 Start Date*: 2014-09-29
    Sponsor Name:Gilead Sciences Inc
    Full Title: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hospitalized Adults with Respirato...
    Medical condition: Respiratory Syncytial Virus (RSV) Infection
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004862 10039247 RSV infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) IT (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2021-000436-62 Sponsor Protocol Number: GS-US-380-4547 Start Date*: 2021-02-12
    Sponsor Name:Gilead Sciences, Inc
    Full Title: A Phase 1, Single-Dose, Cross-Over Study Evaluating the Relative Bioavailability and Food Effect of a Pediatric Tablet for Oral Suspension of Bictegravir/Emtricitabine/Tenofovir Alafenamide and the...
    Medical condition: Human Immunodeficiency Virus (HIV-1) Infection
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2022-001677-31 Sponsor Protocol Number: AMB-001 Start Date*: 2022-10-28
    Sponsor Name:Aarhus University Hospital
    Full Title: Administration of the BCL-2 antagonist, venetoclax, to promote apoptosis of HIV-infected cells and reduce the size of the HIV reservoir: An investigator-initiated phase I/IIb clinical trial in peop...
    Medical condition: HIV-1 infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-001995-23 Sponsor Protocol Number: NIBIT-MESO-1 Start Date*: Information not available in EudraCT
    Sponsor Name:FONDAZIONE NIBIT NETWORK ITALIANO PER LA BIOTERAPIA DEI TUMORI
    Full Title: A SINGLE ARM, PHASE II CLINICAL STUDY OF TREMELIMUMAB COMBINED WITH THE ANTI-PD-L1 MEDI4736 MONOCLONAL ANTIBODY IN UNRESECTABLE MALIGNANT MESOTHELIOMA SUBJECTS: NIBIT-MESO-1 STUDY
    Medical condition: UNRESECTABLE MALIGNANT MESOTHELIOMA
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027406 Mesothelioma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-000474-35 Sponsor Protocol Number: AF219-010 Start Date*: 2015-07-07
    Sponsor Name:Afferent Pharmaceuticals, Inc.
    Full Title: A Dose Escalation Study to Assess the Efficacy and Tolerance of AF-219 in Subjects with Refractory Chronic Cough
    Medical condition: Chronic cough
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-000304-26 Sponsor Protocol Number: GS-US-162-0112 Start Date*: 2015-01-29
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Rollover Protocol to Provide Subjects Completing the FTC-203 Study in South Africa with Continued Access to Emtricitabine.
    Medical condition: Human Immunodeficiency Virus, Type 1 (HIV-1) Infection
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004862 10068341 HIV-1 infection LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2018-003458-26 Sponsor Protocol Number: DEBATE Start Date*: 2019-03-25
    Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA DI MODENA
    Full Title: Evaluating inflammatory and immunological changes of HIV-positive patients switching to DTG dual regimen compared to those switching to a triple drugs regimen (B/F/TAF).
    Medical condition: HIV infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-001235-12 Sponsor Protocol Number: GULLIVER-2 Start Date*: 2021-07-20
    Sponsor Name:Galecto Biotech AB
    Full Title: GULLIVER-2 - a single (open-label) and repeat dose (randomised, placebo-controlled) trial to assess the safety, tolerability and pharmacokinetics of GB1211 (Gal-3 inhibitor) in participants with he...
    Medical condition: Healthy subjects (for study Parts 1 and 3) and patients with hepatic impairment (Child Pugh B and Child Pugh C) (cirrhosis)
    Disease: Version SOC Term Classification Code Term Level
    22.1 100000004871 10052254 Hepatic impairment LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2015-005333-49 Sponsor Protocol Number: ALN-TTRSC-006 Start Date*: 2016-06-30
    Sponsor Name:Alnylam Pharmaceuticals, Inc.
    Full Title: A Multicenter, Multinational, Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of Revusiran in Patients with Transthyretin-mediated Familial Amyloidotic Cardiomyopathy
    Medical condition: Transthyretin (TTR) mediated familial amyloidotic cardiomyopathy (FAC)
    Disease: Version SOC Term Classification Code Term Level
    18.1 10010331 - Congenital, familial and genetic disorders 10016202 Familial amyloidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-001187-33 Sponsor Protocol Number: APD811-301 Start Date*: 2019-02-12
    Sponsor Name:Arena Pharmaceuticals, Inc.
    Full Title: A StuDy eVAluatiNg the EffiCacy and Safety of RalinEpag To Improve Treatment OUTCOMES in PAH Patients
    Medical condition: pulmonary arterial hypertension (PAH)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10077731 Pulmonary hypertension WHO functional class I LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) SE (Prematurely Ended) GB (GB - no longer in EU/EEA) HU (Trial now transitioned) DK (Trial now transitioned) PL (Trial now transitioned) CZ (Trial now transitioned) BE (Trial now transitioned) BG (Trial now transitioned) NL (Trial now transitioned) GR (Trial now transitioned) PT (Trial now transitioned) IT (Trial now transitioned) HR (Completed) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-002632-23 Sponsor Protocol Number: IFO21_02 Start Date*: 2021-12-22
    Sponsor Name:ISTITUTI FISIOTERAPICI OSPITALIERI
    Full Title: A proof-of-concept, biomarker-driven, phase-II clinical trial to explore the activity of decitabine repurposing against advanced, refractory, KRAS-dependent pancreatic ductal adenocarcinoma (PDAC):...
    Medical condition: Advanced (locally advanced or metastatic), pre-treated PDAC patients, progressing after at least one and no more than two lines of systemic therapy, whose tumors express a KRAS-dependency signature.
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10051971 Pancreatic adenocarcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-000947-26 Sponsor Protocol Number: CLFF571X2201 Start Date*: 2012-08-28
    Sponsor Name:Novartis Farmacéutica S.A
    Full Title: Multi-center, randomized, evaluator-blind, active-controlled, parallel-group design to determine safety, tolerability, and efficacy of multiple daily administration of LFF571 for 10 days in patien...
    Medical condition: Clostridium difficile infections
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10054236 Clostridium difficile infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) PT (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 18 15:34:05 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA